ConductScience.org, home

Paper35740211

Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand.

Rattanaumpawan P and 4 others. Antibiotics (Basel), 2022. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand. Papers, record 35740211. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35740211

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand.
PubMed
Journal
Antibiotics (Basel)
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
1.79
iCite
Revised in PubMed
2022-07-16
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rattanaumpawan PPinyohttps://orcid.org/0000-0002-2964-6732
2Jirajariyavej SSupunnee
3Lerdlamyong KKanokorn
4Palavutitotai NNattawan
5Saiyarin JJatuporn

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R016333038Faculty of Medicine Siriraj Hospital, Mahidol University, ThailandPubMed

Source PubMed

Download CSV of grants

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128231247Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.PLoS Negl Trop Dis2017https://conductscience.org/library/papers/28231247PubMed
231822885Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection.J Infect Dis2020https://conductscience.org/library/papers/31822885PubMed
332346491Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.Engineering (Beijing)2020https://conductscience.org/library/papers/32346491PubMed
435470021The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.Int J Infect Dis2022https://conductscience.org/library/papers/35470021PubMed
532958718A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/32958718PubMed
631986264Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet2020https://conductscience.org/library/papers/31986264PubMed
734750163Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports.BMJ2021https://conductscience.org/library/papers/34750163PubMed
828769016Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.Proc Jpn Acad Ser B Phys Biol Sci2017https://conductscience.org/library/papers/28769016PubMed
935026375Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial.Clin Microbiol Infect2022https://conductscience.org/library/papers/35026375PubMed
1034849615Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.Clin Infect Dis2022https://conductscience.org/library/papers/34849615PubMed
1133930706Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.Int Immunopharmacol2021https://conductscience.org/library/papers/33930706PubMed
1233212256Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.Int J Infect Dis2021https://conductscience.org/library/papers/33212256PubMed
1332250385Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.JAMA2020https://conductscience.org/library/papers/32250385PubMed
1427553371Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014.Clin Infect Dis2016https://conductscience.org/library/papers/27553371PubMed
1535535140Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting.Int J Gen Med2022https://conductscience.org/library/papers/35535140PubMed
1632423584Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.Lancet2020https://conductscience.org/library/papers/32423584PubMed
1734539392Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial.Front Pharmacol2021https://conductscience.org/library/papers/34539392PubMed
1834937145Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.N Engl J Med2022https://conductscience.org/library/papers/34937145PubMed
1932302078Clinical Characteristics of Covid-19 in New York City.N Engl J Med2020https://conductscience.org/library/papers/32302078PubMed
2034941423A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.Sci Transl Med2022https://conductscience.org/library/papers/34941423PubMed

See all 23 referencesDownload CSV of references

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
40465794In-hospital mortality outcomes of favipiravir in patients with moderate to severe COVID-19 infection: An emulated target trial using real-world data from the largest field hospital in Thailand.PLoS One2025https://conductscience.org/library/papers/40465794PubMed
40420912Preparation, and ex vivo and in vivo Characterization of Favipiravir-Loaded Aspasomes and Niosomes for Nose-to-Brain Administration.Int J Nanomedicine2025https://conductscience.org/library/papers/40420912PubMed
39509583Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure.Pharmacol Res Perspect2024https://conductscience.org/library/papers/39509583PubMed
38770366Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.Int J Gen Med2024https://conductscience.org/library/papers/38770366PubMed
38493271Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19.Inflammopharmacology2024https://conductscience.org/library/papers/38493271PubMed
37689754Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV).Sci Rep2023https://conductscience.org/library/papers/37689754PubMed
37374302The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study.Medicina (Kaunas)2023https://conductscience.org/library/papers/37374302PubMed
36776761Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand.Lancet Reg Health Southeast Asia2023https://conductscience.org/library/papers/36776761PubMed
36678542Favipiravir-Tautomeric and Complexation Properties in Solution.Pharmaceuticals (Basel)2022https://conductscience.org/library/papers/36678542PubMed
36661514A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors.Curr Issues Mol Biol2023https://conductscience.org/library/papers/36661514PubMed
36603821An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand.Infect Chemother2023https://conductscience.org/library/papers/36603821PubMed
36521656COVID-19 signalome: Potential therapeutic interventions.Cell Signal2023https://conductscience.org/library/papers/36521656PubMed
36160358Perspective: repurposed drugs for COVID-19.Arch Med Sci2022https://conductscience.org/library/papers/36160358PubMed
35685498Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.Int J Clin Pract2022https://conductscience.org/library/papers/35685498PubMed
35543795Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?Geroscience2022https://conductscience.org/library/papers/35543795PubMed
35535140Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting.Int J Gen Med2022https://conductscience.org/library/papers/35535140PubMed
35470021The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.Int J Infect Dis2022https://conductscience.org/library/papers/35470021PubMed
35214034Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline.Pharmaceutics2022https://conductscience.org/library/papers/35214034PubMed
34548811Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study.Int J Gen Med2021https://conductscience.org/library/papers/34548811PubMed
33526596Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/33526596PubMed

See all 24 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35740211

GET https://conductscience.org/api/papers/v1/35740211/references?page=2